drugset
drugset / Trial / NCT03808922

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922 ↗

Phase 3 Recruiting 274 enrolled Ansun Biopharma, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.

Timeline

Start
2019-05-23
Primary completion
2028-09-01
Completion
2028-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DAS181 Protein / enzyme biologic 2.5 mg Other
Subject DAS181 Protein / enzyme biologic 4.5 mg Other

Indications

COVID-19 immunodeficiency disease parainfluenza infectious disease respiratory tract infectious disorder